At a glance
LGHT charges 0.85% a year, above the 0.52% average of the 3 funds most like it (the most expensive of 4). It has $2.5M in assets, the 4th largest of that group. Over the past year it returned +4.3% with distributions reinvested (S&P 500: +11.5%), 2nd of those 4 funds. Its ten largest positions make up 59.8% of the fund, out of 28 in all.
The short version
Langar Global HealthTech ETF (LGHT) is an actively managed fund that held 28 U.S. and foreign healthcare technology stocks as of June 30, 2026, led by Intuitive Surgical, ResMed and Moderna. Its adviser picks stocks rather than tracking an index, which may suit investors wanting a focused bet on this niche. The tradeoffs: it costs 0.85% a year, above the 0.52% average of similar funds, and held only about $2.5 million in assets.
Price history
The interactive chart needs JavaScript.
LGHT +4.3% over the year to Oct 27, 2026, total return with distributions reinvested.
How it has behaved
| YTD | 1 yr | 3 yr | 5 yr | 10 yr | Since start | |
|---|---|---|---|---|---|---|
| LGHT official prospectus, to Dec 31, 2025 | — | -1.51% | — | — | — | -0.07% |
| LGHT price data to Oct 27, 2026 | +11.3% | +4.3% | — | — | — | +3.2% |
- Over the year to Oct 27, 2026, LGHT returned +4.3%, 2nd of 4 among similar funds.
- Its worst full calendar year was 2025 (-1.7%); its best was 2025 (-1.7%).
- The deepest fall in its price history was 28.6% (Jan 30, 2025 to May 15, 2026), recovered by Oct 15, 2026.
Show as a table
| Year | Price data | Prospectus (official) |
|---|---|---|
| 2026 (to date) | +11.3% | — |
| 2025 | -1.7% | -1.15% |
| 2024 | -0.1% | — |
| 2008 financial crisis stocks fell Oct 9, 2007 – Mar 9, 2009 | Before this security existed |
|---|---|
| 2020 COVID crash stocks fell Feb 19, 2020 – Mar 23, 2020 | Before this security existed |
| 2022 bear market stocks fell Jan 3, 2022 – Oct 12, 2022 | Before this security existed |
What's inside
As of Jun 30, 2026, the fund held 28 securities; the ten largest made up 59.82% of assets, and 16.83% sat in cash and money-market holdings.
| Holding | Weight | |
|---|---|---|
| Intuitive Surgical I | 9.92% | |
| ResMed Inc | 9.11% | |
| Moderna Inc | 7.98% | |
| Veeva Systems Inc | 5.60% | |
| GE HealthCare | 5.41% | |
| IQVIA Holdings Inc | 4.98% | |
| Koninklijke Philips | 4.62% | |
| Insulet Corp | 4.44% | |
| DEXCOM INC COM | 4.01% | |
| Zimmer Biomet Holdin | 3.75% | |
| Siemens Healthineers | 3.19% | |
| BioNTech SE | 2.88% | |
| Align Technology Inc | 2.72% | |
| Sonova Holding AG | 2.61% | |
| iRhythm Holdings | 2.39% |
By country
United States 68.47%Germany 6.07%Netherlands 4.62%Switzerland 2.61%Ireland 1.42%By asset type
Stocks 83.19%By sector
Sectors of the companies held, for the 43.5% of the fund in companies that have a stock page here; other holdings and cash aren't classified. Source: N-PORT holdings report as of Jun 30, 2026. Cash, money-market funds and derivatives are shown separately from the securities list.What changed recently
- Over the three months to Jun 30, 2026, investors withdrew a net $946K (creations minus redemptions, per the N-PORT report).
- Monthly total returns reported for that quarter: -5.08%, -0.79%, +4.28%.
How it works
LGHT does not track an index. Its adviser, Langar Investment Management, picks the stocks. Normally at least 80% of assets go into healthcare technology companies of any size listed in the U.S. and other developed countries, held directly or through American Depositary Receipts (ADRs), U.S.-traded certificates that represent foreign shares. A qualifying company, such as a robotic surgery or telemedicine firm, must use technology to fix ongoing problems for patients, doctors, insurers or hospitals and earn most of its revenue that way.
Picks go through four steps. First, the adviser re-sorts healthcare companies from the Global Industry Classification Standard (GICS), a common industry labeling system, into nine HealthTech subsectors, such as Clinical Trials and Hospital Operations. Second, the Langar Rating, developed by Langar Holdings, scores each company's finances, controversies, management and culture, and screens out so-called vice businesses such as tobacco, gambling and weapons. Third, an Industry Risk Score rates each company's risks and helps set its weight. Finally, an investment committee reviews the picks.
The fund is non-diversified, meaning it can concentrate in fewer companies. As of June 30, 2026, it held 28 stocks and no derivatives, the top 10 were about 60% of assets, and about 17% was cash. Turnover was 51.92%, meaning roughly half the portfolio changed over a year.
What it really costs
- LGHT charges 0.85% a year, versus an average of 0.52% for the similar funds below (4th of 4, cheapest first).
- Using the prospectus's standard example, $10,000 invested would cost about $87 in the first year and $1,049 over 10 years (assuming a 5% annual return).
| Cost of $10,000 (SEC example) | 1 yr | 3 yrs | 5 yrs | 10 yrs |
|---|---|---|---|---|
| LGHT | $87 | $271 | $471 | $1,049 |
In a retirement portfolio
LGHT is a small, non-diversified bet on one healthcare niche, with big price swings and no income, so it fits at most as a modest add-on to broader holdings.
LGHT launched January 10, 2024, so it has no record from the 2008, 2020 or 2022 slumps. Its weakest calendar year by price was 2025, down just 1.7%, but that hides a deeper slide. The fund fell 28.6% from a January 30, 2025 peak to a May 15, 2026 low and did not regain that peak until October 15, 2026, about five months after the low. Withdrawing during that stretch meant cashing in shares at depressed prices.
LGHT has no distributions on record, so it adds no income. It charges 0.85% a year, versus a 0.52% average for similar funds; in the SEC's standard example, $10,000 earning 5% yearly incurs $1,049 in costs over 10 years. Its small size, about $2.5 million as of June 30, 2026, adds closure risk. Past results don't predict the future, and a plan should weigh the whole portfolio, not one fund.
Who it may suit — and who should look elsewhere
May suit
- Investors wanting a manager-picked healthcare technology basket, led by Intuitive Surgical, ResMed and Moderna as of June 30, 2026, rather than an index fund.
- Growth-focused investors seeking a small satellite stake who can tolerate swings like its 28.6% drop from January 2025 to May 2026.
- Investors who value a screen that excludes companies tied to tobacco, gambling, weapons, predatory lending and other so-called vice areas.
Look elsewhere if
- Cost-conscious investors: its 0.85% expense ratio (yearly fee) is the highest of four similar funds compared; Global X HealthTech ETF (HEAL) charges 0.50%.
- Retirees who need regular income: LGHT has no distributions on record, so withdrawals mean trimming shares, possibly after a steep drop.
- Investors wary of tiny funds: LGHT held about $2.5 million as of June 30, 2026, and its adviser is new, raising closure risk.
Close alternatives
Matched by holdings overlap from the latest N-PORT reports.
Net assets from each fund's latest N-PORT or annual report where available. Returns through Oct 27, 2026.Questions investors ask
What stocks are in LGHT?
LGHT holds healthcare technology stocks. As of June 30, 2026, it owned 28, and its 10 largest positions made up about 60% of assets. The top five were Intuitive Surgical (9.92%), ResMed (9.11%), Moderna (7.98%), Veeva Systems (5.6%) and GE HealthCare (5.41%). U.S. companies made up about 68% of assets. Foreign names included Philips, Siemens Healthineers, BioNTech and Sonova. About 17% of the fund sat in cash.
How has LGHT performed since launch?
LGHT was roughly flat from its January 10, 2024 launch through December 31, 2025. Its prospectus shows an average annual return of -0.07% over that span and a 1.15% loss in 2025. Its strongest quarter gained 6.97% (ended June 30, 2025) and its weakest lost 3.82% (ended September 30, 2025). Based on market prices, it gained 11.3% from the start of 2026 through October 27, 2026, and 4.3% over the year ended that day. That record is short.
Does LGHT pay dividends?
No. LGHT has no distributions on record since its January 10, 2024 launch, so it does not provide a regular income stream. Its stated goal is long-term growth of capital. Anyone drawing cash from it would have to cash in shares instead, which can be painful after a slide like its 28.6% fall from January 30, 2025 to May 15, 2026.
What's the difference between LGHT and HEAL?
The main differences are cost, size and recent returns. Both focus on healthcare technology, and their holdings overlap by about 39%, based on their latest SEC holdings reports. LGHT is actively managed and charges 0.85% a year; Global X HealthTech ETF (HEAL) charges 0.50%. HEAL held about $31.2 million as of August 31, 2026, versus about $2.5 million for LGHT as of June 30, 2026. Over the year to October 27, 2026, LGHT returned 4.3% while HEAL lost 6.4%.
Is LGHT a risky ETF?
Yes, LGHT carries more risk than a broad stock fund. It is non-diversified, meaning it can concentrate in fewer companies; it held 28 stocks as of June 30, 2026, with about 60% in the top 10. Its volatility, a measure of how widely returns swing, was 25.5% over the year to October 27, 2026. It is also tiny, at about $2.5 million, and its prospectus warns that a fund that fails to attract enough assets could be liquidated, or closed.